TEST:

Altera

ABL1 (ABL proto-oncogene 1), AKT1 (V-akt murine thymoma viral oncogene homolog 1), ARID1A (AT-rich interaction domain 1A), ARID1B (AT-Rich Interaction Domain 1B), AURKA (Aurora kinase A), AURKB (Aurora Kinase B), AXIN1 (Axin 1), BCL2 (B-cell CLL/lymphoma 2), BCL2L1 (BCL2-like 1), BCOR (BCL6 Corepressor), BIRC3 (Baculoviral IAP repeat containing 3), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1), CCND1 (Cyclin D1), CCND2 (Cyclin D2), CCND3 (Cyclin D3), CDKN1A (Cyclin-dependent kinase inhibitor 1A), CDKN1B (Cyclin dependent kinase inhibitor 1B), CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), CDKN2B (Cyclin Dependent Kinase Inhibitor 2B), CDKN2C (Cyclin Dependent Kinase Inhibitor 2C), CHEK1 (Checkpoint kinase 1), CHEK2 (Checkpoint kinase 2), EGFR (Epidermal growth factor receptor), ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3), ERBB4 (erb-b2 receptor tyrosine kinase 4), EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit), FANCA (FA Complementation Group A), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), FOXA1 (Forkhead Box A1), GNAS (GNAS Complex Locus), HER-2 (Human epidermal growth factor receptor 2), HRAS (Harvey rat sarcoma viral oncogene homolog), HRD (Homologous Recombination Deficiency), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), IGF1R (Insulin-like growth factor 1 receptor), IL7R (Interleukin 7 Receptor), JAK2 (Janus kinase 2), JAK3 (Janus Kinase 3), KMT2A (Lysine Methyltransferase 2A), KRAS (KRAS proto-oncogene GTPase), MALT1 (MALT1 Paracaspase), MSH2 (MutS Homolog 2), MSH6 (MutS homolog 6), MSI (Microsatellite instability), NOTCH1 (Notch 1), NOTCH2 (Notch 2), NOTCH3 (Notch Receptor 3), NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1), NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2), NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3), PDGFRA (Platelet Derived Growth Factor Receptor Alpha), PDGFRB (Platelet Derived Growth Factor Receptor Beta), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), POLE (DNA Polymerase Epsilon), PTCH1 (Patched 1), PTEN (Phosphatase and tensin homolog), RHOA (Ras homolog family member A), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), SETBP1 (SET Binding Protein 1), SMAD2 (SMAD Family Member 2), SMAD3 (SMAD Family Member 3), SMAD4 (SMAD family member 4), SMO (Smoothened Frizzled Class Receptor), STAG2 (Stromal Antigen 2), STAG3 (Stromal Antigen 3), STAT3 (Signal Transducer And Activator Of Transcription 3), STAT4 (Signal Transducer And Activator Of Transcription 4), TET1 (Tet Methylcytosine Dioxygenase 1), TET2 (Tet Methylcytosine Dioxygenase 2), TMB (Tumor Mutational Burden), TP53 (Tumor protein P53), VEGFA (Vascular endothelial growth factor A), mTOR (Mechanistic target of rapamycin kinase)